An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Inclusion Criteria: * Completed a Phase I or II YM155 study with at least stable disease and continues to meet the criteria as stated in the previous YM155 study that allows for additional treatment with YM155 * Lack of progression based on the most recent radiological imaging, biochemical assessments and/or physical examination * Negative pregnancy test result (females of child-bearing potential) Exclusion Criteria: * More than 21 days (or 14 days depending on the study of origin) between the time the last infusion of YM155 was stopped in the previous study and the proposed start of the first infusion in this study